Curasight is a clinical phase II company with a technology built around the uPAR receptor, which is a biomarker expressed in most solid cancers. Curasight operates in the diagnosis and treatment of various cancers.
The company has developed a radiopharmaceutical platform that can be used both for diagnostics and for the treatment of cancer: uTRACE – which is used for cancer diagnostics has been used in more than 400 patients in a number of completed and ongoing investigator-initiated phase II clinical trials; and uTREAT – which have been successfully used in the treatment of cancer in translational studies.
What you see is what you treat!
Curasight is a successful Danish theranostic (both diagnostic and treatment) Phase 2 biotech company focusing on diagnosing and treating cancer through Targeted Radionuclide Therapy – currently in brain cancer, prostate cancer, head and neck cancer and neuroendocrine cancer. With Curasight’s technology (uTRACE and uTREAT), cancer can be diagnosed and treated at the cellular level, so that what you can detect of cancer is what you treat with radiation: What you see is what you treat.
The mainstay of Curasight’s investment case is therefore a conviction that Cursasight’s targeted radiotherapy and diagnostics will initially achieve positive progress in the development/studies and thus that the company will be interesting for partnerships with e.g. Big Pharma and achieve the company’s objectives.
Curasight’s objectives are:
Kapital Partner performs or has within the last 12 months performed corporate finance, market relations, investor relations, Certified Adviser or other advisory activities for the following listed companies: NORD.investments, Biosergen, InterMail, Pila Pharma, Hypefactors, Curasight, Evaxion, Re-Match, Audientes, Mdundo.com, Nexcom.